Product Name | Nocodazole |
Description |
Microtubule inhibitor |
Purity | >98% (HPLC); NMR (conforms) |
CAS No. | 31430-18-9 |
Molecular Formula | C14H11N3O3S |
Molecular Weight | 301.3 |
Field of Use | Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only. |
Storage Temperature | -20ºC |
Shipping Temperature | Shipped Ambient |
Product Type | Inhibitor |
Solubility | May be dissolved in DMSO (10 mg/ml, warm) |
Source | Synthetic |
Appearance | White to off-white powder. |
SMILES | COC(=O)NC1=NC2=C(N1)C=CC(=C2)C(=O)C3=CC=CS3 |
InChI | InChI=1S/C14H11N3O3S/c1-20-14(19)17-13-15-9-5-4-8(7-10(9)16-13)12(18)11-3-2-6-21-11/h2-7H,1H3,(H2,15,16,17,19) |
InChIKey | KYRVNWMVYQXFEU-UHFFFAOYSA-N |
Safety Phrases |
Classification: Caution: Substance not yet fully tested. Safety Phrases: S22 - Do not breathe dust S24/25 - Avoid contact with skin and eyes S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection Hazard Phrases: H341- Suspected of causing genetic defects. H361d – Suspected of damaging the unborn child Precautionary Phrases: P281 – Use personal protective equipment as required. |
Cite This Product | Nocodazole (StressMarq Biosciences Inc., Victoria BC CANADA, Catalog # SIH-367) |
Alternative Names | Methyl (5-[2-thienylcarbonyl]-1H-benzimidazol-2-yl |
Research Areas | Apoptosis, Cancer, Neuroscience |
PubChem ID | 4122 |
Scientific Background | Nocodazole also known as Oncodazole. It is an antimitotic agent, associated with the activity of depolymerization of the microtubules (1). Nocadozole has high affinity with Tubulin but little is known on the mechanism of binding. Studies have shown that Nocadozole binds differently to the various α/β isotypes of Tubulin. By measuring the dissociation constants, with the given binding sites, a novel approach of therapeutic agents is under study (2). |
References |
1. Vasquez RJ., Howell B., Yvon AM., Wadsworth P., Cassimus L. (1997) Mol Biol Cell. 8(6): 973-985. 2. Kelian Xu., Schwarz P,. Luduena R,. (2002) Drug Drug Dev.Re. 55: 91-96. |
Reviews
There are no reviews yet.